Journal Mobile Options
Table of Contents
Vol. 19, No. 2-3, 2005
Issue release date: February 2005
Dement Geriatr Cogn Disord 2005;19:154–157

Association Analysis of Apolipoprotein E Genotype and Risk of Depressive Symptoms in Alzheimer’s Disease

Craig D. · Hart D.J. · McIlroy S.P. · Passmore A.P.
Department of Geriatric Medicine, Queen’s University of Belfast, Belfast, Northern Ireland

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objectives: Behavioural and psychological symptoms of dementia (BPSD) are potent predictors of carer distress and admission to institutional care. In Alzheimer’s disease (AD), depressive symptoms are one of the most common complaints affecting around 50% of all patients. There is speculation these symptoms result from known genetic risk factors for AD, therefore we investigated the role of apolipoprotein E ε4 in the aetiology of depression in AD. Methods: In this well-characterised cohort (n = 404) from the relatively genetically homogeneous Northern Ireland population, we tested the hypothesis that genetic variants of apolipoprotein E influence the risk for depressive symptoms in AD patients using the Neuropsychiatric Inventory (NPI-D) to determine the presence of depressive symptoms during the dementing illness. Results: A total of 55% of patients exhibited a history of depression/dysphoria during the course of the illness as gathered by the NPI-D questionnaire. Forty-six percent were suffering from depression/dysphoria when the analysis was restricted to the month prior to interview. No statistically significant association between genotypes or alleles of apolipoprotein E and depression/dysphoria in AD was observed, nor was any association noted between the presence of severe symptoms and genotypes/alleles of apolipoprotein E. Conclusions: These results suggest apolipoprotein E genotype creates no additional risk for depressive symptoms in AD.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Mortimer JA, Ebbitt B, Jun SP, Finch MD: Predictors of cognitive and functional progression in patients with probable Alzheimer’s disease. Neurology 1992;42:1689–1696.
  2. Magni E, Binetti G, Bianchetti A, Trabucchi M: Risk of mortality and institutionalization in demented patients with delusions. J Geriatr Psychiatry Neurol 1996;9:123–126.
  3. Finkel SI: Behavioural and psychological symptoms of dementia: A clinical and research update. Int Psychogeriatr 2000;12(suppl 1):9–12.

    External Resources

  4. Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD: Provisional diagnostic criteria for depression of Alzheimer disease: Rationale and background. Am J Geriatr Psychiatry 2002;10:129–141.
  5. Zubenko GS: Neurobiology of major depression in Alzheimer’s disease. Int Psychogeriatr 2000;12(suppl 1):217–230.

    External Resources

  6. Pearlson GD, Ross CA, Lohr WD, Rovner BW, Chase GA, Folstein MF: Association between family history of affective disorder and the depressive syndrome of Alzheimer’s disease. Am J Psychiatry 1990;147:452–456.
  7. Strauss ME, Ogrocki PK: Confirmation of an association between family history of affective disorder and the depressive syndrome in Alzheimer’s disease. Am J Psychiatry 1996;153:1340–1342.
  8. Levy ML, Cummings JL, Fairbanks LA, Sultzer DL, Small GW: Apolipoprotein E genotype and noncognitive symptoms in Alzheimer’s disease. Biol Psychiatry 1999;45:422–425.
  9. Harwood DG, Barker WW, Ownby RL, St George-Hyslop P, Duara R: Apolipoprotein-E (APO-E) genotype and symptoms of psychosis in Alzheimer’s disease. Am J Geriatr Psychiatry 7:119–123.
  10. Muller-Thomsen T, Arlt S, Ganzer S, Mann U, Mass R, Naber D, Beisiegel U: Depression in Alzheimer’s disease might be associated with apolipoprotein E epsilon 4 allele frequency in women but not in men. Dement Geriatr Cogn Disord 2002;14:59–63.
  11. Holmes C, Russ C, Kirov G, Aitchison KJ, Powell JF, Collier DA, Lovestone S: Apolipoprotein E: Depressive illness, depressive symptoms, and Alzheimer’s disease. Biol Psychiatry 1998;43:159–164.
  12. Ballard C, Massey H, Lamb H, Morris C: Apolipoprotein E: Non-cognitive symptoms and cognitive decline in late onset Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1997;63:273–274.
  13. Ramachandran G, Marder K, Tang M, Schofield PW, Chun MR, Devanand DP, et al: A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer’s disease. Neurology 1996;47:256–259.
  14. Lyketsos CG, Baker L, Warren A, Steele C, Brandt J, Steinberg M, et al: Depression, delusions, and hallucinations in Alzheimer’s disease: No relationship to apolipoprotein E genotype. J Neuropsychiatry Clin Neurosci 1997;9:64–67.
  15. Bodmer JG, Kennedy LJ, Lindsay J, Wasik AM: Applications of serology and the ethnic distribution of three locus HLA haplotypes. Br Med Bull 1987;43:94–121.
  16. Liede A, Cohen BB, Black DM, Davidson RH, Renwick A, Hoodfar E, et al: Evidence of a founder BRCA1 mutation in Scotland. Br J Cancer 2000;82:705–711.
  17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  18. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  19. Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S, Masterman D, et al: Assessing the impact of neuropsychiatric symptoms in Alzheimer’s disease: The Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc 1988;46:210–215.
  20. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
  21. Crook R, Hardy J, Duff K: Single-day apolipoprotein E genotyping. J Neurosci Methods 1994;53:125–127.
  22. Eustace A, Coen R, Walsh C, Cunningham CJ, Walsh JB, Coakley D, Lawlor BA: A longitudinal evaluation of behavioural and psychological symptoms of probable Alzheimer’s disease. Int J Geriatr Psychiatry 2002;17:968–973.
  23. Hope T, Keene J, Fairburn CG, Jacoby R, McShane R: Natural history of behavioural changes and psychiatric symptoms in Alzheimer’s disease. A longitudinal study. Br J Psychiatry 1999;174:39–44.

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00